Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Unknown 3Terminated 2Recruiting 2Not yet recruiting 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Breast Neoplasms 332Neoplasms 221Prostatic Neoplasms 197Carcinoma, Non-Small-Cell Lung 156Lung Neoplasms 134Pancreatic Neoplasms 118Colorectal Neoplasms 102Neoplasm Metastasis 100Carcinoma, Hepatocellular 96Leukemia, Myeloid, Acute 94Multiple Myeloma 91Brain Neoplasms 89Lymphoma 86Head and Neck Neoplasms 76Melanoma 73Ovarian Neoplasms 72Leukemia 71Leukemia, Lymphocytic, Chronic, B-Cell 69Glioblastoma 69Precursor Cell Lymphoblastic Leukemia-Lymphoma 66Colonic Neoplasms 61Recurrence 59Lymphoma, Non-Hodgkin 54Rectal Neoplasms 50Hematologic Neoplasms 50Lymphoma, Follicular 49Glioma 49Squamous Cell Carcinoma of Head and Neck 47Lymphoma, Large B-Cell, Diffuse 47Carcinoma, Renal Cell 46

Interventions

Temozolomide 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × OTHER × Neuroectodermal Tumors × Clear all
NCT02689336 2019-09-09

Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors

Washington University School of Medicine

Phase 2 Withdrawn
CNSGenitourinarySarcoma

Ependymoma, Glioma, Medulloblastoma, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡